Trexquant Investment LP bought a new stake in Agilent Technologies, Inc. (NYSE:A) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,011 shares of the medical research company’s stock, valued at approximately $238,000.

A number of other large investors have also bought and sold shares of the company. Trust Co. of Vermont boosted its stake in Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock valued at $145,000 after buying an additional 205 shares during the last quarter. Penserra Capital Management LLC raised its position in Agilent Technologies by 9.5% in the first quarter. Penserra Capital Management LLC now owns 3,496 shares of the medical research company’s stock valued at $184,000 after buying an additional 304 shares during the period. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC raised its position in Agilent Technologies by 17.2% in the second quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 3,319 shares of the medical research company’s stock valued at $196,000 after buying an additional 486 shares during the period. Coconut Grove Bank raised its position in Agilent Technologies by 84.7% in the first quarter. Coconut Grove Bank now owns 3,750 shares of the medical research company’s stock valued at $198,000 after buying an additional 1,720 shares during the period. Finally, ELM Advisors LLC purchased a new position in Agilent Technologies during the second quarter valued at approximately $202,000.

Agilent Technologies, Inc. (A) opened at 61.74 on Tuesday. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $62.42. The firm has a market cap of $19.88 billion, a price-to-earnings ratio of 31.84 and a beta of 1.30. The stock has a 50 day moving average price of $60.37 and a 200-day moving average price of $56.33.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.07. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $0.49 EPS. Equities analysts forecast that Agilent Technologies, Inc. will post $2.31 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/22/trexquant-investment-lp-invests-238000-in-agilent-technologies-inc-a.html.

Several research firms have commented on A. Bank of America Corporation lifted their price target on Agilent Technologies from $66.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 16th. Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research report on Wednesday, August 16th. Deutsche Bank AG set a $68.00 price target on Agilent Technologies and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Janney Montgomery Scott lifted their price target on Agilent Technologies from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $70.00 price target on shares of Agilent Technologies in a research report on Wednesday, August 16th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $63.18.

In related news, insider Dominique Grau sold 13,007 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $62.00, for a total value of $806,434.00. Following the sale, the insider now directly owns 60,098 shares in the company, valued at approximately $3,726,076. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Didier Hirsch sold 5,710 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $60.60, for a total value of $346,026.00. The disclosure for this sale can be found here. In the last three months, insiders sold 88,036 shares of company stock worth $5,315,704.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.